Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial
Peter MacCallum Cancer Centre · The University of Melbourne · +19 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
475
total citations
- FWCI
- 28.68
- Percentile
- 100%
- References
- 21
Citations per year
Authors
58Topics & keywords
Topics
Keywords
- Trastuzumab
- Medicine
- Oncology
- Panacea (medicine)
- Pembrolizumab
- Breast cancer
- Internal medicine
- Gynecology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.